UA101497C2 - Конъюгаты фактора ix с увеличенным временем полужизни - Google Patents

Конъюгаты фактора ix с увеличенным временем полужизни

Info

Publication number
UA101497C2
UA101497C2 UAA201013989A UAA201013989A UA101497C2 UA 101497 C2 UA101497 C2 UA 101497C2 UA A201013989 A UAA201013989 A UA A201013989A UA A201013989 A UAA201013989 A UA A201013989A UA 101497 C2 UA101497 C2 UA 101497C2
Authority
UA
Ukraine
Prior art keywords
factor
conjugates
life
increased half
contamination
Prior art date
Application number
UAA201013989A
Other languages
English (en)
Ukrainian (uk)
Inventor
Уилльям ХЕНРИ
Original Assignee
Селтик Фарма Пег Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Селтик Фарма Пег Лтд. filed Critical Селтик Фарма Пег Лтд.
Publication of UA101497C2 publication Critical patent/UA101497C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Данное изобретение относится к конъюгатам фактора IX, которые модифицированы для включения биосовмещенного полимерного фрагмента. Конъюгаты фактора IX по сути свободны от загрязнения фактором IXa. Конъюгаты фактора IX имеют улучшенные фармакокинетические свойства, такие как увеличенное время полужизни, позволяющее снизить дозирование и частоту введения.
UAA201013989A 2008-04-24 2009-04-24 Конъюгаты фактора ix с увеличенным временем полужизни UA101497C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4754408P 2008-04-24 2008-04-24
PCT/IB2009/005763 WO2009130602A2 (en) 2008-04-24 2009-04-24 Factor ix conjugates with extended half-lives

Publications (1)

Publication Number Publication Date
UA101497C2 true UA101497C2 (ru) 2013-04-10

Family

ID=41171051

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201013989A UA101497C2 (ru) 2008-04-24 2009-04-24 Конъюгаты фактора ix с увеличенным временем полужизни

Country Status (22)

Country Link
US (1) US20110183906A1 (ru)
EP (1) EP2280734B1 (ru)
JP (1) JP2011519833A (ru)
KR (1) KR20110016440A (ru)
CN (1) CN102046205A (ru)
AU (1) AU2009239641B2 (ru)
BR (1) BRPI0911350A2 (ru)
CA (1) CA2722169A1 (ru)
CO (1) CO6300965A2 (ru)
CR (1) CR11763A (ru)
DK (1) DK2280734T3 (ru)
EC (1) ECSP10010632A (ru)
ES (1) ES2466340T3 (ru)
IL (1) IL208908A0 (ru)
MX (1) MX2010011672A (ru)
MY (1) MY158228A (ru)
NI (1) NI201000177A (ru)
NZ (1) NZ588854A (ru)
RU (1) RU2496521C2 (ru)
UA (1) UA101497C2 (ru)
WO (1) WO2009130602A2 (ru)
ZA (1) ZA201007559B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2101821T3 (da) 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
BR112012001814A8 (pt) 2009-07-27 2018-02-06 Baxalta GmbH Conjugados de proteína de coagulação sanguínea
EP3081233B1 (en) 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
EP2467166A2 (en) * 2009-08-20 2012-06-27 CSL Behring GmbH Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
MX375112B (es) * 2010-07-09 2025-03-06 Biogen Hemophilia Inc Polipéptidos de factor ix y métodos para usarlos.
ES2800983T3 (es) 2010-12-22 2021-01-07 Baxalta GmbH Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína
EP3412314A1 (en) * 2011-05-27 2018-12-12 Baxalta GmbH Therapeutic proteins conjugated to polysialic acid and methods of preparing same
HK1200695A1 (en) * 2012-04-16 2015-08-14 Cantab Biopharmaceuticals Patents Limited Optimised subcutaneous therapeutic agents
BR112014031613A2 (pt) * 2012-06-19 2017-07-25 Polytherics Ltd processo para preparação de conjugados de anticorpos e conjugados de anticorpos
WO2014052490A1 (en) 2012-09-25 2014-04-03 Biogen Idec Ma Inc. Methods of using fix polypeptides
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
AR099340A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados del factor de coagulación ix
EA202092926A3 (ru) 2014-03-24 2021-10-29 Биовератив Терапьютикс Инк. Лиофилизированные составы, содержащие фактор ix
GB2564389A (en) 2017-07-04 2019-01-16 Green Running Ltd A system and method for utility management

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
WO2001058935A2 (en) * 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
KR101031206B1 (ko) * 2002-12-31 2011-04-27 넥타르 테라퓨틱스 말레암산 중합체 유도체 및 이의 바이오컨쥬게이트
ATE444984T1 (de) * 2002-12-31 2009-10-15 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
US7910661B2 (en) * 2003-01-06 2011-03-22 Nektar Therapeutics Thiol-selective water-soluble polymer derivatives
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
ATE455174T1 (de) 2003-09-23 2010-01-15 Univ North Carolina Zellen, die vitamin-k-reduktase und vitamin-k- abhängiges protein coexprimieren und deren anwendung zur verbesserung der produktivität von diesem vitamin-k-abhängigen protein
JP4855074B2 (ja) * 2003-09-30 2012-01-18 一般財団法人化学及血清療法研究所 高純度血液凝固ｉｘ因子調製物およびその精製方法
EP2272951B1 (en) 2003-10-14 2014-07-23 Baxter International Inc. Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
JP2008505119A (ja) * 2004-06-30 2008-02-21 ネクター セラピューティクス アラバマ，コーポレイション 高分子−第ｉｘ因子部分の抱合体
WO2006063292A1 (en) 2004-12-08 2006-06-15 Icos Corporation Recombinant method for making multimeric proteins
KR101310532B1 (ko) 2005-02-28 2013-09-23 박스터 헬쓰케어 에스에이 비타민 ｋ 의존성 단백질 발현의 개선을 위한 비타민 ｋ에폭사이드 환원효소 소단위 １의 재조합 동시발현
CA2601574C (en) 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
US20080255026A1 (en) * 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
WO2007126808A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc Pegylated factor viii
AU2007253264A1 (en) * 2006-05-24 2007-11-29 Novo Nordisk Health Care Ag Factor IX analogues having prolonged in vivo half life
JP5737821B2 (ja) * 2006-08-17 2015-06-17 一夫 大橋 血友病ｂ治療剤及びその製造方法

Also Published As

Publication number Publication date
JP2011519833A (ja) 2011-07-14
MY158228A (en) 2016-09-15
WO2009130602A2 (en) 2009-10-29
WO2009130602A3 (en) 2010-02-11
EP2280734B1 (en) 2014-02-26
RU2010147813A (ru) 2012-05-27
CO6300965A2 (es) 2011-07-21
BRPI0911350A2 (pt) 2017-12-05
AU2009239641A1 (en) 2009-10-29
RU2496521C2 (ru) 2013-10-27
US20110183906A1 (en) 2011-07-28
DK2280734T3 (da) 2014-05-26
ES2466340T3 (es) 2014-06-10
AU2009239641B2 (en) 2013-11-07
WO2009130602A9 (en) 2010-04-22
EP2280734A2 (en) 2011-02-09
CA2722169A1 (en) 2009-10-29
HK1151986A1 (en) 2012-02-17
KR20110016440A (ko) 2011-02-17
MX2010011672A (es) 2011-03-02
NZ588854A (en) 2011-12-22
NI201000177A (es) 2011-08-29
IL208908A0 (en) 2011-01-31
ECSP10010632A (es) 2011-02-28
CR11763A (es) 2011-04-26
CN102046205A (zh) 2011-05-04
ZA201007559B (en) 2012-01-25

Similar Documents

Publication Publication Date Title
MY158228A (en) Factor ix conjugates with extended half-lives
MY158890A (en) Pegylated insulin lispro compounds
EP4253395A3 (en) Processes for the preparation of carbohydrate conjugated rna agents
WO2012068531A3 (en) Novel compositions and uses of anti-hypertension agents for cancer therapy
MX356826B (es) Conjugados de molecula pequeña para suministro intracelular de compuestos biologicamente activos.
MX2010003299A (es) Oligonucleotidos muy cortos (micromirs).
NZ599880A (en) Use of bethanechol for treatment of xerostomia
MX2010009222A (es) Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos.
TN2012000161A1 (en) Spiro-oxindole mdm2 antagonists
MX2013003452A (es) Conjugados de amatoxina con enlazantes mejorados.
PT2313111E (pt) Formulações de agonista de receptor do tipo toll e seus usos
MX2010009154A (es) Moleculas conjugadas del factor viii.
WO2013067199A3 (en) Subcutaneous delivery of polymer conjugates of therapeutic agents
JO3026B1 (ar) مستضادات ببتيد شبيه الجلوكاجون - 2
MX2012010448A (es) Conjugados de carbohidrato-poli aminoacido-farmaco.
MX362266B (es) Composiciones oftalmicas con retención y proteccion de desecación mejoradas.
EP2131849A4 (en) COMPOSITIONS AND METHODS OF DISTRIBUTING AGENTS AGAINST CANCER
PH12017502392A1 (en) Targeted conjugates and particles and formulations thereof
WO2011054837A3 (de) Bifunktionale prodrugs und drugs
MX2012006265A (es) Formulaciones disacaridas hipersulfatadas.
HK1204962A1 (en) Cyclodextrin-based polymers for therapeutic delivery
MX2018004696A (es) Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.
MX2012003230A (es) Composiciones farmaceuticas de rapamicina.
TR201104008T1 (tr) Bir antitümör ilacının oluşturulmasına ve stabilizasyonuna ilişkin yöntemler.
NZ593169A (en) Anticancer compounds